As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says
This article was originally published in The Pink Sheet Daily
The Irish company is still dealing with the after-effects of splitting apart its business in 2011, including its search for a new CEO. Meanwhile, Elan’s lead revenue driver, Tysabri continues to grow.
You may also be interested in...
Deadly brain disease casts shadow over a quarter in which the company reports progress on new launches, including hemophilia, but PML occurred in only one in 100,000 treated and experience suggests risk can be managed.
Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.
With the release of “unprecedented” data on its Phase III MS candidate alemtuzumab and its once-daily oral therapy teriflunomide already under regulatory review, Sanofi looks for a leadership role in the increasingly fragmented market it expects will approach $20 billion by 2016.